Page 27 - Noble-Virtual-Healthcare-2024

Ensysce Biosciences, Inc.

SELECTED FINANCIAL ITEMS ENSC

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue 0.79 0.49 0.44 0.52 2.23
Gross Profit (1.01) (1.15) (1.48) (1.72) (5.36)
Gross Margin -127% -235% -340% -334% -240%
EBIT (2.56) (2.29) (2.71) (3.16) (10.72)
EBIT Margin -324% -468% -622% -613% -481%
Net Income to Common Shareholders (2.19) (2.24) (2.69) (3.50) (10.63)
Net Margin -278% -457% -618% -680% -476%

Balance Sheet Key Items
Total Assets 3.91 6.36 3.22 2.71 2.71
Cash & Short Term Investments 1.42 3.83 1.46 1.12 1.12
% of Assets 36% 60% 45% 41% 41%
Current Assets -Total 3.37 5.86 2.76 2.29 2.29
% of Assets 86% 92% 86% 85% 85%
Total Liabilities 4.07 2.56 2.06 3.36 3.36
% of Assets 104% 40% 64% 124% 124%
Current Liabilities - Total 3.98 2.52 2.03 3.33 3.33
% of Assets 102% 40% 63% 123% 123%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (0.15) 3.79 1.16 (0.65) (0.65)
% of Assets -4% 60% 36% -24% -24%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.61) (3.11) (2.26) (1.80) (10.78)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 1.87 5.52 (0.10) 1.46 8.76

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference